{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:34:09Z","timestamp":1793327649083,"version":"4.5.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Spinal muscular atrophy (SMA) is a neuromuscular genetic disorder caused by the loss of lower motor neurons leading to progressive muscle weakness and atrophy. With the rise of novel therapies and early diagnosis on newborn screening (NBS), the natural history of SMA has been evolving. Earlier therapeutic interventions can modify disease outcomes and improve survival. The role of treatment in infants born preterm is an important question given the importance of early intervention. In this study, we discuss the case of an infant born at 32 weeks who was diagnosed with SMA on NBS and was treated with Spinraza<jats:sup>\u00ae<\/jats:sup> (Nusinersen) and Zolgensma<jats:sup>\u00ae<\/jats:sup> (Onasemnogene abeparvovec-xioi) within the first 2 months of life. With the scarce evidence that currently exists, clinicians should be aware of the efficacy and safety impact of early therapy particularly in the preterm infant.<\/jats:p>","DOI":"10.3389\/fneur.2023.1230889","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T05:13:50Z","timestamp":1694582030000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Case report: A case of spinal muscular atrophy in a preterm infant: risks and benefits of treatment"],"prefix":"10.3389","volume":"14","author":[{"given":"Elisa","family":"Nigro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Grunebaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binita","family":"Kamath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Licht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Malcolmson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aamir","family":"Jeewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranesh","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Tarnopolsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan","family":"Gonorazky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.24497","article-title":"Spinal muscular atrophy: diagnosis and management in a new therapeutic era","volume":"51","author":"Arnold","year":"2005","journal-title":"Muscle Nerve."},{"key":"B2","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3390\/cells11030417","article-title":"Restoring SMN expression: an overview of the therapeutic developments for the treatment of spinal muscular atrophy","volume":"11","author":"Aslesh","year":"2022","journal-title":"Cells."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1172\/JCI124120","article-title":"Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment","volume":"129","author":"Ramos","year":"2019","journal-title":"J Clin Invest"},{"key":"B5","year":"2022","journal-title":"Newborn Screening Ontario Program 2022"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ng.3389","article-title":"Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas","volume":"47","author":"Nault","year":"2015","journal-title":"Nature Genetics"},{"key":"B7","unstructured":"2022"},{"key":"B8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/mus.27261","article-title":"Time is muscle: a recommendation for early treatment for preterm infants with spinal muscular atrophy","volume":"64","author":"Lee","year":"2001","journal-title":"Muscle Nerve."},{"key":"B9","article-title":"Durham: Novartis Gene Therapies, Inc","year":"2021"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1038\/s41372-021-01083-w","article-title":"Postnatal steroid management in preterm infants with evolving bronchopulmonary dysplasia","volume":"41","author":"Htun","year":"2021","journal-title":"J Perinatol Off J Perin Assoc."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2431-1-1","article-title":"The adverse neuro-developmental effects of postnatal steroids in the preterm infant: A systemic review of RCTs","volume":"1","author":"Barrington","year":"2001","journal-title":"BMC Pediatric."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e221947","DOI":"10.1001\/jamanetworkopen.2022.1947","article-title":"Dexamethasone, prednisolone, and methylprednisolone use and 2-year neurodevelopmental outcomes in extremely preterm infants","volume":"5","author":"Puia-Dumitrescu","year":"2022","journal-title":"JAMA network open."},{"key":"B13","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/nep.12028","article-title":"When birth comes early: effects on nephrogenesis","volume":"18","author":"Black","year":"2013","journal-title":"Nephrology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.2174\/0929867328666211101102227","article-title":"Nephrogenesis, renal function, and biomarkers in preterm newborns","volume":"25","author":"Corr\u00eaa","year":"2022","journal-title":"Curr Med Chem"},{"key":"B16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1055\/s-2003-37948","article-title":"Risk factors for neonatal thrombocytopenia in preterm infants","volume":"20","author":"Beiner","year":"2003","journal-title":"Am J Perinatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1080\/09537104.2020.1742879","article-title":"Changes in megakaryopoiesis over ontogeny and their implications in health and disease","volume":"31","author":"Davenport","year":"2020","journal-title":"Platelets"},{"key":"B18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/tme.12587","article-title":"Platelet transfusion thresholds in premature neonates (PlaNeT-2 trial)","volume":"29","author":"Estcourt","year":"2019","journal-title":"Transf Med."},{"key":"B19","first-page":"0319","article-title":"Neonatal jaundice","volume":"2011","author":"Woodgate","year":"2011","journal-title":"BMJ Clin Evid."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.3390\/jcm10173896","article-title":"Effect of preterm birth on cardiac and cardiomyocyte growth and the consequences of antenatal and postnatal glucocorticoid treatment","volume":"10","author":"Vrselja","year":"2021","journal-title":"J Clin Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0022-3476(95)70410-8","article-title":"Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infant","volume":"126","author":"Brozanski","year":"1995","journal-title":"J Pediatr."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1230889\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T05:13:53Z","timestamp":1694582033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1230889\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":21,"alternative-id":["10.3389\/fneur.2023.1230889"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1230889","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,12]]},"article-number":"1230889"}}